We Believe Interactions with Health Care Professionals Bring Value to Patient Care
AbbVie is committed to collaborating with health care professionals (HCPs), health care organizations (HCOs) and patient organizations to improve patient health across the globe. Our interactions with HCPs, HCOs and patient organizations are guided by openness and transparency to ensure public trust and confidence. AbbVie supports disclosure of these relationships wherever possible to demonstrate the integrity of our relationships with HCPs, HCOs and patient organizations.
HCP/HCO Disclosures Inside the US
Open Payments—Physician Payments Sunshine Act
The US Sunshine Act, also known as the Open Payments—Physician Payments Sunshine Act, was enacted as federal law in 2010 as a component of the Affordable Care Act. The Act requires health care manufacturers, including AbbVie, to track financial transactions with certain health care providers and health care organizations (HCOs) and to disclose those transactions on an annual basis. We support the Act and its goal of providing the public greater visibility into interactions between the health care industry and HCPs to ensure public trust and confidence. To learn more, view our FAQs.
The report is based on transactional data that has been aggregated at a particular point in time; some payments and transfers of value that take place during the reporting period may be included in the next quarter’s report. Posted data may not correlate to state transparency reports due to differences in the scope and requirements between the various transparency laws. Changes or additions that are identified after the report is posted will be accounted for in the next quarter’s report. Due to the requirements for reporting related entities/payees, some payments shown on the report are included more than once. The types of payments and transfers of value included in the report are as follows:
- Business Meals, which include reimbursed amounts for meals incurred in the course of providing contracted-for services such as consulting and research; and meals provided in connection with an educational or business discussion
- Business Travel, which includes reimbursed amounts and the value of directly provided transportation (e.g., airfare, taxi service) incurred in the course of providing contracted-for services such as consulting and research
- Educational Materials and Items, which include reference materials such as journal articles, textbooks and anatomical models
- Professional Services,
which include payments for contracted-for services such as speaking
at an educational seminar or serving on a data safety monitoring
- Research-Related Payments, which include payments for research and clinical trial activities, royalties and license fees
- Job Interview-related
payments, such as flights, meals, hotel, area tours, etc. Your
collected information will only be released on the public website if
you are selected to interview and have expenses paid for or
reimbursed to you by AbbVie. Additionally, Massachusetts and Vermont
have expanded rulings that require interview-related expenses to be
reported for “Health Care Providers & Practitioners.” Expenses
incurred during the interview process may be reported under the
Federal Sunshine Act (and other State laws).
For Physician Payment Reports, AbbVie follows the annual de minimis threshold reporting guidance as provided by CMS for Open Payments reporting.
If you have questions on the data contained in the reports, please email TransparencyReporting@abbvie.com.
HCP/HCO Disclosures Outside of the US
Information exchanged with Healthcare Professionals (HCPs),
Healthcare Organizations (HCOs) and patient organizations has led to
newer and better therapies and, most importantly, enhanced care for
patients. We believe our collaboration with HCPs, HCOs and patient
organizations bring value to patient care through optimizing treatment
options and changing the way diseases impact lives. Our interactions
with them are based on trust, transparency and integrity, with a goal
of providing the public with greater visibility into these
interactions to ensure public trust and confidence. AbbVie engages in
a range of activities from clinical research to sponsorships to
educational activities to exchange information on how new medicines
fit into the patient pathway. By bringing greater transparency to
these relationships, AbbVie demonstrates its ongoing commitment to
strengthening the basis for future collaboration.